Evidence map›Paper›PMID 40974527›Full record

ArticleScience China. Life sciences2026

AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer.

Yuhan Zhao, Chi Xu, Yiqiu Liu, Ye Zhu, Lingling Fan, Fangyan Gao, Xiaojie Liang, Yaqin Shi, Yongbin Chen, Xiaoxiang Guan

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuhan Zhao *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Chi Xu *Department of Breast Surgery, Peking Union Medical College Hospital, Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Yiqiu Liu *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Ye Zhu *Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Lingling FanDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Fangyan GaoDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Xiaojie LiangDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Yaqin ShiDepartment of Oncology, the First Affiliated Hospital of Soochow University, Suzhou, 215000, China. shiyaqinand@126.com.
Yongbin ChenThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. ybchen@mail.kiz.ac.cn.
Xiaoxiang GuanDepartment of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. xguan@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer, notably lacks effective treatment strategies. Although androgen receptor (AR) has emerged as a potential therapeutic target for TNBC, monotherapy with AR inhibitors has proven to be of restricted efficacy. Aiming to develop superior therapeutic approaches, a comprehensive drug library screening was conducted. The ERK inhibitor GDC-0994 exhibited significant synergistic effects with the AR inhibitor bicalutamide. Transcriptome sequencing showed that this combination therapy activates ferroptosis, as evidenced by elevated ROS, increased Fe

Indexed as

Extracellular Signal-Regulated MAP KinasesFerroptosisForkhead Transcription FactorsReceptors, AndrogenTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDrug SynergismEpithelial-Mesenchymal TransitionFemaleHumansMAP Kinase Signaling SystemMiceSignal TransductionAR protein, humanExtracellular Signal-Regulated MAP KinasesForkhead Transcription Factorsmesenchyme fork head 1 proteinReceptors, Androgencombination treatmentferroptosisFOXC2synergistic effecttriple-negative breast cancer

Identifiers

PMID40974527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.